ECSP066303A - Uso de antagonistas del receptor de angiotensina ii - Google Patents
Uso de antagonistas del receptor de angiotensina iiInfo
- Publication number
- ECSP066303A ECSP066303A EC2006006303A ECSP066303A ECSP066303A EC SP066303 A ECSP066303 A EC SP066303A EC 2006006303 A EC2006006303 A EC 2006006303A EC SP066303 A ECSP066303 A EC SP066303A EC SP066303 A ECSP066303 A EC SP066303A
- Authority
- EC
- Ecuador
- Prior art keywords
- ppargamma
- angiotensin
- inhibitor
- telmisartan
- activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La invención se refiere al uso de antagonistas del receptor de la angiotensina II para el tratamiento de personas en las que se diagnosticó diabetes mellitus de tipo 2 o existe sospecha de una prediabetes, para la prevención de diabetes o para el tratamiento del síndrome metabólico y la resistencia a la insulina en pacientes con presión arterial normal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10335027A DE10335027A1 (de) | 2003-07-31 | 2003-07-31 | Verwendung von Angiotensin II Rezeptor Antagonisten |
DE10346260A DE10346260A1 (de) | 2003-07-31 | 2003-10-06 | Verwendung von Angiotensin II Rezeptor Antagonisten |
DE10356815A DE10356815A1 (de) | 2003-07-31 | 2003-12-05 | Verwendung von Angiotensin II Rezeptor Antagonisten |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066303A true ECSP066303A (es) | 2006-10-25 |
Family
ID=34119379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006303A ECSP066303A (es) | 2003-07-31 | 2006-01-23 | Uso de antagonistas del receptor de angiotensina ii |
Country Status (29)
Country | Link |
---|---|
US (1) | US20050070594A1 (es) |
EP (3) | EP2263670B1 (es) |
JP (1) | JP4833840B2 (es) |
KR (1) | KR20060054404A (es) |
CN (3) | CN101926997A (es) |
AT (1) | ATE443519T1 (es) |
AU (1) | AU2004260606B2 (es) |
BR (1) | BRPI0413165A (es) |
CA (1) | CA2534006C (es) |
CY (1) | CY1109560T1 (es) |
DE (4) | DE10335027A1 (es) |
DK (2) | DK2119441T3 (es) |
EA (2) | EA017640B1 (es) |
EC (1) | ECSP066303A (es) |
ES (2) | ES2543722T3 (es) |
HK (1) | HK1093305A1 (es) |
HU (1) | HUE027274T2 (es) |
IL (1) | IL172693A (es) |
ME (1) | MEP51108A (es) |
MX (1) | MXPA06001322A (es) |
NO (1) | NO335444B1 (es) |
NZ (1) | NZ544877A (es) |
PL (2) | PL1651213T5 (es) |
PT (1) | PT1651213E (es) |
RS (1) | RS50793B (es) |
SI (1) | SI1651213T2 (es) |
UA (1) | UA83854C2 (es) |
WO (1) | WO2005011680A1 (es) |
ZA (1) | ZA200509835B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA007485B1 (ru) * | 2001-02-24 | 2006-10-27 | Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
ES2452019T5 (es) * | 2004-11-05 | 2021-06-28 | Boehringer Ingelheim Int | Comprimido bicapa que comprende telmisartán y amlodipino |
CN1298389C (zh) * | 2005-01-18 | 2007-02-07 | 广东省人民医院 | 一种含替米沙坦和钙离子拮抗剂的复方降压制剂及其应用 |
WO2006136916A2 (en) * | 2005-06-20 | 2006-12-28 | Glenmark Pharmaceuticals Limited | Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
CA2625646A1 (en) * | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
CN101260103A (zh) * | 2007-03-09 | 2008-09-10 | 上海艾力斯医药科技有限公司 | 一类具有部分PPARγ激动剂活性的化合物及其应用 |
EP2134326B1 (en) * | 2007-04-17 | 2011-11-16 | Ratiopharm GmbH | Pharmaceutical compositions comprising irbesartan |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
CN101869567A (zh) * | 2009-04-24 | 2010-10-27 | 北京奥萨医药研究中心有限公司 | 含有双胍类降糖药物和沙坦类降压药物的药物组合物及其用途 |
WO2010133638A1 (de) | 2009-05-20 | 2010-11-25 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische telmisartan-trinklösung |
KR101069166B1 (ko) * | 2009-06-02 | 2011-09-30 | 한국화학연구원 | 이미다조 페닐테트라졸 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 골다공증 또는 비만의 예방 또는 치료용 약학적 조성물 |
CN107115530A (zh) | 2009-11-27 | 2017-09-01 | 勃林格殷格翰国际有限公司 | 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗 |
KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
CN102971005A (zh) | 2010-06-24 | 2013-03-13 | 贝林格尔.英格海姆国际有限公司 | 糖尿病治疗 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
KR102117282B1 (ko) * | 2010-11-15 | 2020-06-01 | 베링거 인겔하임 인터내셔날 게엠베하 | 혈관보호성 및 심장보호성 항당뇨 치료요법 |
EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
RU2699508C1 (ru) * | 2018-07-25 | 2019-09-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ лечения больных метаболическим синдромом |
CN114073697B (zh) * | 2021-01-19 | 2023-01-24 | 复旦大学附属肿瘤医院 | Bcat2抑制剂在制备预防和/或治疗bcat2介导的相关代谢疾病药物中的用途 |
WO2022213353A1 (en) | 2021-04-09 | 2022-10-13 | Peking University | Sirna, medical compositions, and methods for treating diabetes using the same |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4265847A (en) * | 1978-03-30 | 1981-05-05 | Kirby Pharmaceuticals Ltd | Tabletting process |
JPS5671074A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
CA1338238C (en) | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
US4880804A (en) | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
IE70593B1 (en) | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
DE19675036I2 (de) | 1990-02-19 | 2004-10-21 | Novartis Ag | Acylverbindungen. |
NZ237476A (en) | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
IE912956A1 (en) | 1990-09-10 | 1992-03-11 | Abbott Lab | Angiotensin ii receptor antagonists |
SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5196537A (en) | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
US6162802A (en) * | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
EP0872235A1 (en) | 1992-04-13 | 1998-10-21 | Zeneca Limited | Therapeutic agents |
US5824696A (en) | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
WO1995026188A1 (en) | 1994-03-29 | 1995-10-05 | Merck & Co., Inc. | Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles |
US5496831A (en) * | 1994-05-13 | 1996-03-05 | The General Hospital Corporation | Inhibition of insulin-induced adiposis |
EP0831911B1 (en) * | 1995-06-07 | 2002-04-17 | G.D. Searle & Co. | Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
US6087386A (en) * | 1996-06-24 | 2000-07-11 | Merck & Co., Inc. | Composition of enalapril and losartan |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
WO1999065500A1 (en) * | 1998-06-17 | 1999-12-23 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
EP1870098A3 (en) * | 1998-07-10 | 2010-07-07 | Novartis Ag | Combined use of valsartan and calcium channel blockers for therapeutic purposes |
AU1042199A (en) * | 1998-11-06 | 2000-05-29 | Boehringer Ingelheim International Gmbh | Antihypertensive medicaments containing lacidipine and telmisartan |
UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
PT1197223E (pt) * | 1999-04-28 | 2005-04-29 | Takeda Pharmaceutical | Preventivos/medicamentos/inibidores da progressao de retinopatia simples ou retinopatia pre-proliferativa |
EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
CN1651087A (zh) * | 2000-04-12 | 2005-08-10 | 诺瓦提斯公司 | 有机化合物的联合形式 |
US6784207B2 (en) * | 2000-08-04 | 2004-08-31 | Roche Vitamins Inc. | Phytanic acid derivative compositions |
EP1353727A2 (en) * | 2000-12-01 | 2003-10-22 | Novartis AG | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction |
US20030078190A1 (en) * | 2001-05-25 | 2003-04-24 | Weinberg Marc S. | Methods for tissue protection using highly effective inhibition of the renin-angiotensin system |
JP2003113120A (ja) * | 2001-08-03 | 2003-04-18 | Takeda Chem Ind Ltd | 徐放性医薬 |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
AUPS236902A0 (en) * | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
US8980870B2 (en) * | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
EP1587584B1 (de) * | 2003-01-16 | 2007-05-23 | Boehringer Ingelheim International GmbH | Pharmazeutische kombination zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten |
DE10306179A1 (de) * | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
US9029363B2 (en) * | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
-
2003
- 2003-07-31 DE DE10335027A patent/DE10335027A1/de not_active Withdrawn
- 2003-10-06 DE DE10346260A patent/DE10346260A1/de not_active Withdrawn
- 2003-12-05 DE DE10356815A patent/DE10356815A1/de not_active Withdrawn
-
2004
- 2004-07-24 EP EP10177920.5A patent/EP2263670B1/de not_active Revoked
- 2004-07-24 DK DK09160568.3T patent/DK2119441T3/en active
- 2004-07-24 IL IL172693A patent/IL172693A/en not_active IP Right Cessation
- 2004-07-24 MX MXPA06001322A patent/MXPA06001322A/es active IP Right Grant
- 2004-07-24 UA UAA200601929A patent/UA83854C2/uk unknown
- 2004-07-24 EP EP04763484A patent/EP1651213B2/de not_active Revoked
- 2004-07-24 PL PL04763484T patent/PL1651213T5/pl unknown
- 2004-07-24 PL PL09160568T patent/PL2119441T3/pl unknown
- 2004-07-24 SI SI200431301T patent/SI1651213T2/sl unknown
- 2004-07-24 BR BRPI0413165-7A patent/BRPI0413165A/pt active Search and Examination
- 2004-07-24 CA CA2534006A patent/CA2534006C/en not_active Expired - Fee Related
- 2004-07-24 EA EA200900929A patent/EA017640B1/ru not_active IP Right Cessation
- 2004-07-24 EP EP20090160568 patent/EP2119441B1/de not_active Revoked
- 2004-07-24 ES ES09160568.3T patent/ES2543722T3/es active Active
- 2004-07-24 AU AU2004260606A patent/AU2004260606B2/en not_active Revoked
- 2004-07-24 ES ES04763484T patent/ES2334136T5/es active Active
- 2004-07-24 KR KR1020067002186A patent/KR20060054404A/ko active Search and Examination
- 2004-07-24 RS YUP-2006/0066A patent/RS50793B/sr unknown
- 2004-07-24 PT PT04763484T patent/PT1651213E/pt unknown
- 2004-07-24 EA EA200600161A patent/EA012600B1/ru not_active IP Right Cessation
- 2004-07-24 DE DE502004010117T patent/DE502004010117D1/de active Active
- 2004-07-24 HU HUE09160568A patent/HUE027274T2/en unknown
- 2004-07-24 CN CN2010102582634A patent/CN101926997A/zh active Pending
- 2004-07-24 CN CN2011100821828A patent/CN102139110A/zh active Pending
- 2004-07-24 AT AT04763484T patent/ATE443519T1/de active
- 2004-07-24 NZ NZ544877A patent/NZ544877A/en unknown
- 2004-07-24 WO PCT/EP2004/008326 patent/WO2005011680A1/de active Application Filing
- 2004-07-24 JP JP2006521497A patent/JP4833840B2/ja not_active Expired - Fee Related
- 2004-07-24 DK DK04763484.5T patent/DK1651213T4/da active
- 2004-07-24 CN CN2004800220966A patent/CN1829511B/zh not_active Withdrawn - After Issue
- 2004-07-24 ME MEP-511/08A patent/MEP51108A/xx unknown
- 2004-07-27 US US10/899,784 patent/US20050070594A1/en not_active Abandoned
-
2005
- 2005-12-05 ZA ZA200509835A patent/ZA200509835B/xx unknown
-
2006
- 2006-01-23 EC EC2006006303A patent/ECSP066303A/es unknown
- 2006-02-27 NO NO20060938A patent/NO335444B1/no not_active IP Right Cessation
- 2006-12-21 HK HK06114060.0A patent/HK1093305A1/xx not_active IP Right Cessation
-
2009
- 2009-12-04 CY CY20091101278T patent/CY1109560T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066303A (es) | Uso de antagonistas del receptor de angiotensina ii | |
Sica et al. | Blood pressure–lowering efficacy of the fixed‐dose combination of azilsartan medoxomil and chlorthalidone: a factorial study | |
Powers et al. | Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information | |
PT1925303E (pt) | Utilização de antagonistas do receptor tipo 1 da angiotensina ii para a prevenção de diabetes | |
Giamouzis et al. | Epidemiology and importance of renal dysfunction in heart failure patients | |
NO20072325L (no) | Kombinasjonsterapi omfattende telmisartan og hydroklortiazid | |
Hjermitslev et al. | Azilsartan medoxomil, an angiotensin II receptor antagonist for the treatment of hypertension | |
Black et al. | Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: the ACQUIRE randomized double‐blind study | |
EA200401137A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
WO2004075856A3 (en) | Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases | |
Weir et al. | The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed‐dose combination in hypertensive patients with and without high cardiovascular risk | |
Kaplan | Angiotensin II receptor antagonists in the treatment of hypertension | |
Ruilope | Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension | |
CO5560583A2 (es) | Composiciones medicinales que comprenden antagonistas del receptor de angiotensina ii | |
Schmieder | The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm | |
ATE453396T1 (de) | Kombinationspräparat aus einem thiaziddiuretikum und einem schleifendiuretikum | |
TH83710B (th) | การบำบัดรวม | |
Hansson | Hypertension control for a new era: emerging differences among AIIRAs | |
WO2003085127A3 (en) | Method for identification of insulin receptor kinase activators |